MedGenome, an Indian genomics research and diagnostics startup, in a recent study has found out that using a cancer vaccine approach can be applied in Lynch Syndrome treatment.
The study conducted by MedGenome examined the feasibility of a personalized cancer vaccine approach by detecting potential immunogenic tumor specific alterations.
Lynch Syndrome or hereditary non-polyposis colorectal cancer (HNPCC) is a hereditary cancer that develops following a loss of function mutations in DNA mismatch repair genes, including MLH1, MSH2, MSH3, MSH6, PMS2, and EPCAM.
It is the most common type of hereditary colorectal cancer syndrome, making up 2-5% of all forms of colorectal cancers.
Lynch Syndrome can increase the life-time risk of developing other types of cancers of different organs like colon, small intestine, stomach, kidney, liver, brain, uterus, pelvis and prostate.
The incidence of hereditary colorectal cancer syndrome is limited to 4.4 per lakh men and 3.9 per lakh women and a large percentage of patients will develop the cancer before the age of 45 in majority of patients in India.
As per the Cancer Moonshot Blue Ribbon Panel, more than a million Americans suffer from the hereditary colorectal cancer syndrome.
MedGenome through its study found several potential immunogenic peptides from a Lynch Syndrome-affected patient whose condition progressed into colon cancer. The development of cancer was due to lack of anti-tumor immune response in affected person, said MedGenome.
With this study, it can be observed that cancer vaccines can be potentially used to treat or delay the onset or relapse of Lynch Syndrome associated Colorectal Cancer.
Dr. Amit Chaudhuri, the senior author of the MedGenome study, said that with Lynch Syndrome having very less treatment options, the cancer vaccine approach can be tried as monotherapy or in combination with standard immune-oncology or chemotherapy drugs.